Scarica l'app Stockscreener
41.15
3.39%
1.35
Precedente Chiudi:
$39.80
Aprire:
$40.06
Volume 24 ore:
332.30K
Relative Volume:
1.00
Capitalizzazione di mercato:
$3.14B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-16.53
EPS:
-2.49
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
+3.31%
1M Prestazione:
-3.72%
6M Prestazione:
+6.06%
1 anno Prestazione:
+43.23%
Intervallo 1D:
$39.66
$41.62
Intervallo di 1 settimana:
$37.34
$41.62
Portata 52W:
$28.20
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| XENE | 41.15 | 3.14B | 13.17M | -199.06M | -156.53M | -2.49 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals director sells $200,946 in stock - Investing.com
First Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Eye Opportunities With Xenon Pharmaceuticals - Evrim Ağacı
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap DownHere's What Happened - MarketBeat
Equities Analysts Issue Forecasts for XENE FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for XENE Reduced by Cantor Fitzgerald - MarketBeat
How to Take Advantage of moves in (XENE) - Stock Traders Daily
Q1 Earnings Forecast for XENE Issued By HC Wainwright - MarketBeat
What is Wedbush's Estimate for XENE FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Pessimistic View of XENE FY2024 Earnings - MarketBeat
Needham & Company LLC Reaffirms Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Stock Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
GSA Capital Partners LLP Purchases 30,830 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon to Present at Upcoming Investor Conferences - The Manila Times
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals: Q3 Earnings Snapshot - mySA
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlight - GuruFocus.com
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals Reports Q3 2024 Progress and Outlook - TipRanks
Xenon Reports Q3 2024 Financial Results and Business Update - The Manila Times
Xenon Pharmaceuticals Reports $803M Cash Position, Advances Epilepsy Drug Pipeline | XENE Stock News - StockTitan
Earnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2 - GuruFocus.com
TimesSquare Capital Management LLC Purchases 23,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Fiera Capital Corp Sells 28,679 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Xenon to Report Q3 2024 Financial Results on November 12, 2024 - StockTitan
Harbor Capital Advisors Inc. Buys 23,947 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
New Horizons in Tonic-clonic Seizure Market Exploring Future - openPR
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by abrdn plc - MarketBeat
Repligen Co. (NASDAQ:RGEN) Position Boosted by Blue Trust Inc. - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Brokerages - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Creative Planning - Defense World
Creative Planning Buys 2,475 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Blue Trust Inc. Has $39,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Assenagon Asset Management S.A. Acquires 138,685 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
When (XENE) Moves Investors should Listen - Stock Traders Daily
SG Americas Securities LLC Sells 18,463 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Leerink Partnrs Has Negative Outlook of XENE FY2026 Earnings - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe - Zacks Investment Research
Millennium Management LLC Increases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc (XENE)’s Day in Review: Closing at 39.42, Down by -3.90 - The Dwinnex
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):